Anti-citrullinated protein/peptide antibodies (ACPA) in rheumatoid arthritis: Specificity and relation with rheumatoid factor

被引:65
作者
Vander Cruyssen, B [1 ]
Peene, I [1 ]
Cantaert, T [1 ]
Hoffman, IEA [1 ]
De Rycke, L [1 ]
Veys, EM [1 ]
De Keyser, F [1 ]
机构
[1] State Univ Ghent Hosp, Dept Rheumatol, B-9000 Ghent, Belgium
关键词
anti-citrullinated peptide/protein antibodies (ACPA); rheumatoid factor; rheumatoid arthritis; specificity;
D O I
10.1016/j.autrev.2005.04.018
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Anti-citrullinated protein/peptide antibodies (ACPA) are highly specific and sensitive markers for rheumatoid arthritis (RA). For instance, for the anti-CCP2 assay, sensitivities ranging from 55% to 80% and specificities ranging from 90% to 98% have been reported. Despite their high specificity, recent reports have suggested that ACPA may be found in some patients with other rheumatic autoimmune diseases, including psoriatic arthritis, systemic lupus erythematosus and Sjogren's syndrome. Also, the differences between the classical rheumatoid factor (RF) and ACPA, as well as the complementarity between both tests have recently been demonstrated more clearly. Indeed, both antibody systems have a different association with specific RA features like extra-articular manifestations, a different association with the HLA shared epitope and, behave differently following anti-TNF therapy. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:468 / 474
页数:7
相关论文
共 41 条
[21]  
Kroot EJJA, 2000, ARTHRITIS RHEUM, V43, P1831, DOI 10.1002/1529-0131(200008)43:8<1831::AID-ANR19>3.0.CO
[22]  
2-6
[23]   Clinical utility of the anti-CCP assay in patients with rheumatic diseases [J].
Lee, DM ;
Schur, PH .
ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 (09) :870-874
[24]   Relationship among the HLA-DRB1 shared epitope, smoking, and rheumatoid factor production in rheumatoid arthritis [J].
Mattey, DL ;
Dawes, PT ;
Clarke, S ;
Fisher, J ;
Brownfield, A ;
Thomson, W ;
Hajeer, AH ;
Ollier, WER .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2002, 47 (04) :403-407
[25]   Use of anti-citrullinated peptide and anti-RA33 antibodies in distinguishing erosive arthritis in patients with systemic lupus erythematosus and rheumatoid arthritis [J].
Mediwake, R ;
Isenberg, DA ;
Schellekens, GA ;
van Venrooij, WJ .
ANNALS OF THE RHEUMATIC DISEASES, 2001, 60 (01) :67-68
[26]   Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody [J].
Mikuls, TR ;
O'Dell, JR ;
Stoner, JA ;
Parrish, LA ;
Arend, WP ;
Norris, JM ;
Holers, VM .
ARTHRITIS AND RHEUMATISM, 2004, 50 (12) :3776-3782
[27]   Specific autoantibodies precede the symptoms of rheumatoid arthritis - A study of serial measurements in blood donors [J].
Nielen, MMJ ;
van Schaardenburg, D ;
Reesink, HW ;
van de Stadt, RJ ;
van der Horst-Bruinsma, IE ;
de Koning, MHMT ;
Habibuw, MR ;
Vandenbroucke, JP ;
Dijkmans, BAC .
ARTHRITIS AND RHEUMATISM, 2004, 50 (02) :380-386
[28]  
NIELSEN M, 2005, ANN RHEUM DIS JAN
[29]   History and diagnostic value of antibodies to citrullinated proteins in rheumatoid arthritis [J].
Peene, I ;
De Rycke, L ;
Baeten, D ;
Hoffman, I ;
Veys, EM ;
De Keyser, F .
INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2004, 17 (02) :107-115
[30]   Anti-cyclic citrullinated peptide antibodies in advanced rheumatoid arthritis [J].
Pinheiro, GC ;
Scheinberg, MA ;
da Silva, MA ;
Maciel, S .
ANNALS OF INTERNAL MEDICINE, 2003, 139 (03) :234-235